Literature DB >> 11295571

Angiotensin III: a central regulator of vasopressin release and blood pressure.

A Reaux1, M C Fournie-Zaluski, C Llorens-Cortes.   

Abstract

Among the main bioactive peptides of the brain renin-angiotensin system, angiotensin (Ang) II and AngIII exhibit the same affinity for type 1 and type 2 AngII receptors. Both peptides, injected intracerebroventricularly, cause similar increases in vasopressin release and blood pressure. Because AngII is converted in vivo to AngIII, the identity of the true effector is unknown. This review summarizes new insights into the predominant role of brain AngIII in the control of vasopressin release and blood pressure and underlines the fact that brain aminopeptidase A, the enzyme forming central AngIII, could constitute a putative central therapeutic target for the treatment of hypertension.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11295571     DOI： 10.1016/s1043-2760(01)00381-2

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN： 1043-2760            Impact factor:   12.015


  27 in total

Review 1.  The significance of brain aminopeptidases in the regulation of the actions of angiotensin peptides in the brain.

Authors:  Robert C Speth; Vardan T Karamyan
Journal:  Heart Fail Rev       Date:  2008-01-09       Impact factor: 4.214

Review 2.  Angiotensin II and vascular injury.

Authors:  Augusto C Montezano; Aurelie Nguyen Dinh Cat; Francisco J Rios; Rhian M Touyz
Journal:  Curr Hypertens Rep       Date:  2014-06       Impact factor: 5.369

3.  Identification and characterization of a functional mitochondrial angiotensin system.

Authors:  Peter M Abadir; D Brian Foster; Michael Crow; Carol A Cooke; Jasma J Rucker; Alka Jain; Barbara J Smith; Tyesha N Burks; Ronald D Cohn; Neal S Fedarko; Robert M Carey; Brian O'Rourke; Jeremy D Walston
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-18       Impact factor: 11.205

4.  Randomised, double-blind, placebo-controlled, dose-escalating phase I study of QGC001, a centrally acting aminopeptidase a inhibitor prodrug.

Authors:  Fabrice Balavoine; Michel Azizi; Damien Bergerot; Nadia De Mota; Rémi Patouret; Bernard P Roques; Catherine Llorens-Cortes
Journal:  Clin Pharmacokinet       Date:  2014-04       Impact factor: 6.447

Review 5.  Role of angiotensin III in hypertension.

Authors:  Annabelle Reaux-Le Goazigo; Xavier Iturrioz; Celine Fassot; Cedric Claperon; Bernard P Roques; Catherine Llorens-Cortes
Journal:  Curr Hypertens Rep       Date:  2005-04       Impact factor: 5.369

Review 6.  Biochemical and enzymatic properties of the M1 family of aminopeptidases involved in the regulation of blood pressure.

Authors:  Masafumi Tsujimoto; Yoshikuni Goto; Masato Maruyama; Akira Hattori
Journal:  Heart Fail Rev       Date:  2007-11-13       Impact factor: 4.214

7.  Endothelial metabolism of angiotensin II to angiotensin III, not angiotensin (1-7), augments the vasorelaxation response in adrenal cortical arteries.

Authors:  Phillip G Kopf; William B Campbell
Journal:  Endocrinology       Date:  2013-10-03       Impact factor: 4.736

Review 8.  Management of vasodilatory shock: defining the role of arginine vasopressin.

Authors:  Martin W Dunser; Volker Wenzel; Andreas J Mayr; Walter R Hasibeder
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 9.  Aldosterone receptor antagonists: biology and novel therapeutical applications.

Authors:  P Magni; M Motta
Journal:  J Endocrinol Invest       Date:  2003-08       Impact factor: 4.256

Review 10.  Brain renin-angiotensin system dysfunction in hypertension: recent advances and perspectives.

Authors:  Shereeni J Veerasingham; Mohan K Raizada
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.